Massive Sanofi deal spells bad news for Zealand
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article7271934.ece/ALTERNATES/schema-16_9/Zealand%2520Pharma%2520bygning.jpg)
The French developer of diabetes drugs Sanofi has signed a global license agreement for a portfolio of long-acting diabetes treatments with Korean company Hamni, which receives EUR 400 million upfront and could be eligible for up to EUR 3.5 billion in milestone payments.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Billion-dollar deal validates Zealand project
For abonnenter
Zealand CEO sees competitive advantage over Novo
For abonnenter
Zealand CEO: We are obligated to be ambitious
For abonnenter